# Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)

> **NCT05797740** · — · ACTIVE_NOT_RECRUITING · sponsor: **Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany** · enrollment: 367 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Mavenclad

## Key facts

- **NCT ID:** NCT05797740
- **Lead sponsor:** Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-03
- **Primary completion:** 2029-01-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 367 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797740, "Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05797740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*